Exelixis enters licensing deal with Wuxi Biologics

8 March 2021

Genomics-based drug discovery company Exelixis (Nasdaq: EXEL) has announced an exclusive license agreement with WuXi Bio (HKG: 2269) to support the continued expansion of its oncology biologics pipeline.

The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind Cabometyx (cabozantinib), the Californian company’s flagship product and global oncology franchise, which received its fourth approval from the US Food and Drug Administration in January.

"We are transforming how biologics are developed"Under the terms of the agreement, Exelixis will make an undisclosed and apparently ‘modest’ upfront payment to WuXi Bio in exchange for an exclusive license to a panel of monoclonal antibodies to a pre-clinically validated target, discovered based on the Chinese firm’s integrated technology platforms, for the development of antibody-drug conjugate, bispecific, and certain other novel tumor-targeting biologics applications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK